Therapeutic use of vitamin D and its analogues in autoimmunity

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 1, 2012, Pages 22-34

  Fletcher, Jean M ^a   Basdeo, Sharee A ^a   Allen, Aideen C ^a   Dunne, Pádraic J ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Analogues; Autoimmunity; Immune modulation; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes; Vitamin D

Indexed keywords

19 NOR VITAMIN D DERIVATIVE; 1ALPHA HYDROXY 2 METHYLENE 19 NORHOMOPREGNACALCIFEROL; 2 METHYLENE 19 NOR 1ALPHA,25 DIHYDROXYVITAMIN D3; 2 METHYLENE 19 NOR VITAMIN D; 2 METHYLENE 19 NOR VITAMIN D DERIVATIVE; 25 HYDROXYVITAMIN D; 2BETA (3 HYDROXYPROPOXY) 1ALPHA, 25 DIHYDROXYVITAMIN D3; ALFACALCIDOL; BETA INTERFERON; CALCITRIOL; CALCIUM; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYTOKINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INECALCITOL; INSULIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR MODULATOR;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM METABOLISM; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG STRUCTURE; DRY EYE; ENTERITIS; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MULTIPLE SCLEROSIS; NONHUMAN; NUTRITIONAL REQUIREMENT; OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SUN EXPOSURE; T LYMPHOCYTE; TREATMENT DURATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DIABETES MELLITUS; HUMANS; MULTIPLE SCLEROSIS; PATENTS AS TOPIC; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84855843122     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312798889239     Document Type: Review

References (150)

1. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: A historical perspective. Pediatrics 2003; 112(2): e132-5.
2. Wang S. Epidemiology of vitamin D in health and disease. Nutr Res Rev 2009; 22(2): 188-203.
3. Holick MF. Skin: Site of the synthesis of vitamin D and a target tissue for the active form, 1,25-dihydroxyvitamin D3. Ann NY Acad Sci 1988; 548: 14-26.
4. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78(4): 1193-231.
5. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000; 120(1): 139-46.
6. Ghazarian JG, Jefcoate CR, Knutson JC, Orme-Johnson WH, De-Luca HF. Mitochondrial cytochrome p450. A component of chick kidney 25-hydrocholecalciferol-1alpha-hydroxylase. J Biol Chem 1974; 249(10): 3026-33.
7. Brown AJ, Slatopolsky E. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008; 29(6): 433-52.
8. Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW. Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med 1985; 105(2): 239-46.
9. Hewison M. Vitamin D and the immune system: New perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39(2): 365-79.
10. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat Rev Immunol 2008; 8(9): 685-98.
11. Sochorova K, Budinsky V, Rozkova D, Tobiasova Z, Dusilova-Sulkova S, Spisek R, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133(1): 69-77.
12. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145(3): 351-7.
13. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270(3): 701-8.
14. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(12): 6800-5.
15. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007; 178(1): 145-53.
16. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005; 106(10): 3490-7.
17. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD-L1. Eur J Immunol 2009; 39(11): 3147-59.
18. van der Aar AM, Sibiryak DS, Bakdash G, van Capel TM, van der Kleij HP, Opstelten DJ, et al. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol 2011; 127(6): 1532-40 e7.
19. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11(4): 344-9.
20. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010; 285(50): 38751-5.
21. Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem 2011; 286(2): 997-1004.
22. Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, Iwakura Y, et al. 1alpha, 25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett 2010; 134(1): 7-16.
23. Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 2011;23(8): 519-28.
24. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183(9): 5458-67.
25. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, et al. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009; 119(2): 387-98.
26. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179(3): 1634-47.
27. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229(11): 1136-42.
28. Kamen DL. Vitamin D in lupus-new kid on the block? Bull NYU Hosp Jt Dis 2010; 68(3): 218-22.
29. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011; 364(3): 248-54.
30. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: 1-164.
31. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD. Vitamin D in adult health and disease: A review and guideline statement from Osteoporosis Canada (summary). CMAJ 2010; 182(12): 1315-9.
32. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, et al. IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int 2010; 21(7): 1151-4.
33. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90(6): 3215-24.
34. Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169(6): 626-32.
35. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011; 96(1): 53-8.
36. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother 2008; 9(1): 107-18.
37. Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010; 9(7): 507-10.
38. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008; 3(5): 1535-41.
39. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev 2010; 9(11): 709-15.
40. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
41. Basile LA, Taylor SN, Wagner CL, Quinones L, Hollis BW. Neonatal vitamin D status at birth at latitude 32 degrees 72': Evidence of deficiency. J Perinatol 2007; 27(9): 568-71.
42. Khoo AL, Chai LY, Koenen HJ, Kullberg BJ, Joosten I, van der Ven AJ, et al. 1,25-dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: Impact of seasonal variation of immune responses. J Infect Dis 2011; 203(1): 122-30.
43. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC. Timing of birth and risk of multiple sclerosis: Population based study. BMJ 2005; 330(7483): 120.
44. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010; 6(3): 156-66.
45. Goodin DS. The causal cascade to multiple sclerosis: A model for MS pathogenesis. PLoS One 2009; 4(2): e4565.
46. Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, Kockum I. Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum Genet 2010; 18(12): 1349-52.
47. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vi tamin D receptor binding: Associations with disease and evolution. Genome Res 2010; 20(10): 1352-60.
48. Karray EF, Ben Dhifallah I, Ben Abdelghani K, Ben Ghorbel I, Khanfir M, Houman H, et al. Associations of vitamin D receptor gene polymorphisms FokI and BsmI with susceptibility to rheumatoid arthritis and Behcet's disease in Tunisians. Joint Bone Spine 2011; [Epub ahead of print].
49. Ramos-Lopez E, Jansen T, Ivaskevicius V, Kahles H, Klepzig C, Oldenburg J, et al. Protection from type 1 diabetes by vitamin D receptor haplotypes. Ann N Y Acad Sci 2006; 1079: 327-34.
50. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011; 60(5): 1624-31.
51. Lopez ER, Regulla K, Pani MA, Krause M, Usadel KH, Badenhoop K. CYP27B1 polymorphisms variants are associated with type 1 diabetes mellitus in Germans. J Steroid Biochem Mol Biol 2004; 89-90(1-5): 155-7.
52. Torkildsen O, Knappskog PM, Nyland HI, Myhr KM. Vitamin Ddependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol 2008; 65(6): 809-11.
53. Orton SM, Ramagopalan SV, Para AE, Lincoln MR, Handunnetthi L, Chao MJ, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 2011; 305(1-2): 116-20.
54. Jain R, von Hurst PR, Stonehouse W, Love DR, Higgins CM, Coad J. Association of vitamin D receptor gene polymorphisms with insulin resistance and response to vitamin D. Metabolism 2011; [Epub ahead of print].
55. Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011; 21(9): 559-64.
56. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979; 29(9 Pt 1): 1228-35.
57. Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988; 111 (Pt 1): 1-25.
58. Taylor BV, Pearson JF, Clarke G, Mason DF, Abernethy DA, Willoughby E, et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010; 16(12): 1422-31.
59. Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, et al. Multiple sclerosis prevalence in Ireland: Relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 2011; 82(3): 317-22.
60. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Rosati G. Multiple sclerosis prevalence among Sardinians: Further evidence against the latitude gradient theory. Neurol Sci 2001; 22(2): 163-5.
61. Gronlie SA, Myrvoll E, Hansen G, Gronning M, Mellgren SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol 2000; 247(2): 129-33.
62. Melcon MO, Gold L, Carra A, Caceres F, Correale J, Cristiano E, et al. Argentine Patagonia: Prevalence and clinical features of multiple sclerosis. Mult Scler 2008; 14(5): 656-62.
63. Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry 2011;82(10): 1132-41.
64. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosisassociated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5(2): e1000369.
65. Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010; 74(23): 1905-10.
66. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9(5): 520-32.
67. Bamford CR, Sibley WA, Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 1983; 33(6): 697-701.
68. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000; 48(2): 271-2.
69. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62(1): 60-5.
70. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: More than just the effects of vitamin D? Nat Rev Immunol 2011; 11(9): 584-96.
71. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci USA 2010; 107(14): 6418-23.
72. Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76(6): 540-8.
73. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002; 408(2): 200-4.
74. Deluca HF, Plum LA. Vitamin D deficiency diminishes the severity and delays onset of experimental autoimmune encephalomyelitis. Arch Biochem Biophys 2011; 513(2): 140-3.
75. Fernandes de Abreu DA, Ibrahim EC, Boucraut J, Khrestchatisky M, Feron F. Severity of experimental autoimmune encephalomyelitis is unexpectedly reduced in mice born to vitamin D-deficient mothers. J Steroid Biochem Mol Biol 2010; 121(1-2): 250-3.
76. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93(15): 7861-4.
77. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005; 175(6): 4119-26.
78. Nashold FE, Spach KM, Spanier JA, Hayes CE. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol 2009; 183(6): 3672-81.
79. Becklund BR, Hansen DW Jr., Deluca HF. Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc Natl Acad Sci USA 2009; 106(13): 5276-81.
80. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, et al. Inhibition of Th1 development and treatment of chronicrelapsing experimental allergic encephalomyelitis by a nonhypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 2000; 30(2): 498-508.
81. Na S, Ma Y, Zhao J, Schmidt C, Zeng QQ, Chandrasekhar S, et al. A nonsecosteroidal vitamin D receptor modulator ameliorates experimental autoimmune encephalomyelitis without causing hypercalcemia. Autoimmune Dis 2011; 2011: 132958.
82. Garcion E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol 2003; 105(5): 438-48.
83. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76(9): 1294-6.
84. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74(23): 1852-9.
85. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86(3): 645-51.
86. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40(6): 627-39.
87. Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 2011; 96(9): 2826-34.
88. Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010; 5(12): e15235.
89. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003; 134(1-2): 128-32.
90. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008; 51(8): 1391-8.
91. Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: Latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 2003; 111(4): 518-23.
92. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001; 358(9292): 1500-3.
93. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann NY Acad Sci 2006; 1079: 310-2.
94. Driver JP, Foreman O, Mathieu C, van Etten E, Serreze DV. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin Exp Immunol 2008; 151(1): 76-85.
95. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulindependent diabetes mellitus. Arch Biochem Biophys 2003; 417(1): 77-80.
96. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory Tcells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51(5): 1367-74.
97. Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 2001; 33(3): 2365.
98. Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998; 65(9): 1225-32.
99. Gysemans C, van Etten E, Overbergh L, Giulietti A, Eelen G, Waer M, et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 2008; 57(1): 269-75.
100. Aljabri KS, Bokhari SA, Khan MJ. Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency. Ann Saudi Med 2010; 30(6): 454-8.
101. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25(5): 411-6.
102. Pitocco D, Crino A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006; 23(8): 920-3.
103. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: The IMDIAB XIII trial. Diabetes Care 2010; 33(9): 1962-3.
104. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33(7): 1443-8.
105. Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 2010; 6(8): 468-76.
106. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50(1): 72-7.
107. Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2008; 67(4): 530-5.
108. Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 2011; 38(1): 53-9.
109. Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(5): 745-7.
110. Zwerina K, Baum W, Axmann R, Heiland GR, Distler JH, Smolen J, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis 2011; 70(6): 1122-9.
111. Larsson P, Mattsson L, Klareskog L, Johnsson C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol 1998; 114(2): 277-83.
112. Tsuji M, Fujii K, Nakano T, Nishii Y. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994; 337(3): 248-50.
113. Brohult J, Jonson B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand J Rheumatol 1973; 2(4): 173-6.
114. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17(4): 453-6.
115. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010; 9(5): A277-87.
116. Nancy AL, Yehuda S. Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 2009; 301(1): 57-64.
117. Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70(9): 1569-74.
118. Szodoray P, Tarr T, Bazso A, Poor G, Szegedi G, Kiss E. The immunopathological role of vitamin D in patients with SLE: Data from a single centre registry in Hungary. Scand J Rheumatol 2011; 40(2): 122-6.
119. Toloza SM, Cole DE, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010; 19(1): 13-9.
120. Urowitz MB, Feletar M, Bruce IN, Ibanez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32(8): 1467-72.
121. Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-Oxa-1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 1990; 36(1): 21-31.
122. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162(3): 633-6.
123. Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, et al. Therapy of psoriasis in childhood and adolescence-a German expert consensus. J Dtsch Dermatol Ges 2011; 9(10): 815-23.
124. Reich K, Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol 2011; 25 (Suppl 4): 15-20.
125. Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon JC, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: A randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20(4): 465-71.
126. Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 2009; 8(8 Suppl): s4-8.
127. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010; 9(12): 941-55.
128. DeLuca, H.F., Barycki, R., Grzywacz, P.K., Plum, L.A., Sicinski, R.R., 2-Alkylidene-18,19-dinor-vitamin D compounds. US20100179344 (2010).
129. DeLuca, H.F., Cantorna, M.T., Humpal-Winter, J. Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis. US6479474 (2002).
130. deLuca, H.F., Glebocka, A., Sokolowska, K., Sicinski, R.R., Plum, L.A., Clagett-Dame, M.19-Nor-vitamin D analogs with 1,2-dihydrofuran ring. WO2010006123 (2010).
131. DeLuca, H.F., Cantorna, M.T. Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds. US20100160267(2010).
132. Takenouchi, K., Gao, Q., Manabe, K., Sogawa, R., Takano, Y., Ishizuka, S. Vitamin D, derivatives and remedies for inflammatory respiratory diseases containing the same. US6531460 (2003).
133. Delansorne, R., Dufour-lamartinie, J.-F. Therapeutical uses of inecalcitol. US20110015276 (2011).
134. Hansen, K.H. Vitamin D analogues and their pharmaceutical use. US6537980 (2003).
135. Hatakeyama, S., Watanabe, H., Kawase, A. 24-hydroxy vitamin D derivatives. US6538145 (2003).
136. Mayne CG, Spanier JA, Relland LM, Williams CB, Hayes CE. 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur J Immunol 2011; 41(3): 822-32.
137. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007; 85(11): 2480-90.
138. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 Signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006; 177(9): 6030-37.
139. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
140. Hayes, C.E., Nashold, F.E. Treating vitamin D responsive diseases. US6989377 (2006).
141. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200(3): 277-85.
142. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, et al. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collageninduced arthritis by rolipram. J Immunol 1997; 159(12): 6253-9.
143. Toussirot E, Streit G, Wendling D. Infectious complications with anti-TNFalpha therapy in rheumatic diseases: A review. Recent Pat Inflamm Allergy Drug Discov 2007; 1(1): 39-47.
144. Lu, J., Ma, T., Nagpal, S., Shen, Q., Warshawsky, A.M., Yee, Y.K., Rupp, M.J. Vitamin D receptor modulators. US7897789 (2011).
145. Bunel, E.E., Gajewski, R.P., Jones, C.D., Lu, J., Nagpal, S., Ma, T., Yee, Y. K. Vitamin D receptor modulators. US7595345 (2009).
146. Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, et al. Novel nonsecosteroidal vitamin D mimics exert VDRmodulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol1999; 6(5): 265-75.
147. Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006; 116(4): 892-904.
148. Itoh, S., Ishii, Y., Mukai, K., Kita, K. Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D. US6410006 (2002).
149. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69(5): 842-56.
150. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88(2): 582S-6S.